Financial information

celebrating 20 years Summarised Group segmental analysis

for the year ended 30 June 2018

2018
Therapeutic Focused Brands R’million Other Pharmaceuticals R’million Total Pharmaceuticals R’million Nutritionals R’million Total
R’million
Revenue 18 934 20 571 39 505 3 091 42 596
Cost of sales (7 946) (11 348) (19 294) (1 697) (20 991)
Gross profit 10 988 9 223 20 211 1 394 21 605
Selling and distribution expenses     (6 578) (882) (7 460)
Contribution profit     13 633 512 14 145
Administrative expenses         (3 103)
Net other operating income         249
Depreciation         740
Normalised EBITDA         12 031
Adjusted for:          
Depreciation         (740)
    Amortisation         (632)
    Loss on sale of assets         (4)
    Impairment of assets         (872)
    Reversal of impairment         130
    Restructuring costs         (199)
    Transaction costs         (160)
    Product litigation costs         (317)
Operating profit         9 237
           
Gross profit (%) 58,0 44,8 51,2 45,1 50,7
Selling and distribution expenses (%)     16,7 28,5 17,5
Contribution profit (%)     34,5 16,6 33,2
Administrative expenses (%)         7,3
Normalised EBITDA (%)         28,2
2017
Therapeutic Focused Brands R’million Other Pharmaceuticals R’million Total Pharmaceuticals R’million Nutritionals R’million Total
R’million
Revenue 17 417 20 572 37 989 3 224 41 213
Cost of sales (8 438) (11 047) (19 485) (1 832) (21 317)
Gross profit 8 979 9 525 18 504 1 392 19 896
Selling and distribution expenses     (5 880) (840) (6 720)
Contribution profit     12 624 552 13 176
Administrative expenses         (2 780)
Net other operating income         320
Depreciation         700
Normalised EBITDA         11 416
Adjusted for:          
Depreciation         (700)
    Amortisation         (567)
    Loss on sale of assets         (196)
    Impairment of assets         (726)
    Reversal of impairment         4
    Restructuring costs         (494)
    Transaction costs         (208)
    Product litigation costs         (208)
Operating profit         8 321
           
Gross profit (%) 51,6 46,3 48,7 43,2 48,3
Selling and distribution expenses (%)     15,5 26,1 16,3
Contribution profit (%)     33,2 17,1 32,0
Administrative expenses (%)         6,7
Normalised EBITDA (%)         27,7
% Change
Therapeutic Focused Brands Other Pharmaceuticals Total Pharmaceuticals Nutritionals Total
Revenue 9 0 4 (4) 3
Cost of sales (6) 3 (1) (7) (2)
Gross profit 22 (3) 9 0 9
Selling and distribution expenses     12 5 11
Contribution profit     8 (7) 7
Administrative expenses         12
Net other operating income         (22)
Depreciation         6
Normalised EBITDA         5